Second, if certain metabolites show strong correlation with FADS1 expression, then nutritional or pharmacological interventions targeting FADS1 or related metabolic pathways—such as the phosphatidylcholine/phosphatidylethanolamine biosynthetic pathway (involving 1-linolenoyl-2-linolenoyl-GPC (18:2/18:3)) and broader fatty-acid metabolic pathways—may represent promising strategies to prevent or mitigate the risk of metabolically driven cancers. Here, FADS1 is linked to cancer.